Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine
10.13481/j.1671-587x.20160224
- VernacularTitle:CDA基因单核苷酸多态性对中晚期非小细胞肺癌接受吉西他滨化疗患者预后的影响
- Author:
Hang ZAO
;
Xu WANG
;
Wei LI
- Publication Type:Journal Article
- Keywords:
lung neoplasms;
cytidine deaminase;
single nucleotide polymorphisms;
chemotherapy;
gemcitabine;
prognosis
- From:
Journal of Jilin University(Medicine Edition)
2016;42(2):316-320
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influence of single nucleotide polymorphisms (SNP ) of cytidine deaminase (CDA)in the curative effect of gemcitabine,and to clarify the correlation of CDA SNP with the clinical prognosis of the advanced non-small cell lung cancer (NSCLC)patients.Methods:CDA 79A>C gene was detected by Sequenom Massarray Genotype System among 93 patients with advanced NSCLC who received chemotherapy of gemcitabine.The associations between CDA 79A>C polymorphisms and progression free survival (PFS)and overall survival (OS)were estimated using Kaplan-meier methods and Log-rank test for univariate analysis, and COX proportional hazards model was used for multivariate analysis.Results:There was no significant correlation between the CDA 79A>C SNPs with the clinical and pathological characteristics of NSCLC patients.The median PFS in the patients with wild genotype A/A was 9.3 months, while the median PFS in the patients with mutant genotype A/C and C/C was 11 months;there was no significant difference between them (P=0.061).The median OS in the patients with wild genotype A/A was 2 1.7 months, and the median OS of the patients with mutant genotype was 22.1 months;there was no significant difference between them (P=0.513).Conclusion:CDA 79A>C SNPs can prolong the PFS of the NSCLC patients,but it does not affect the OS of the patients.
